Research Analysts’ Recent Ratings Updates for Kymera Therapeutics (KYMR)

Posted by ABMN Staff on Jun 16th, 2025

A number of firms have modified their ratings and price targets on shares of Kymera Therapeutics (NASDAQ: KYMR) recently:

6/3/2025 – Kymera Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $60.00 price target on the stock.
6/3/2025 – Kymera Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $57.00 to $64.00. They now have an “overweight” rating on the stock.
6/3/2025 – Kymera Therapeutics was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $79.00 price target on the stock, up previously from $49.00.
6/3/2025 – Kymera Therapeutics was upgraded by analysts at B. Riley from a “neutral” rating to a “buy” rating. They now have a $60.00 price target on the stock, up previously from $38.00.
6/2/2025 – Kymera Therapeutics was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating. They now have a $51.00 price target on the stock.
5/22/2025 – Kymera Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
5/20/2025 – Kymera Therapeutics is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $55.00 price target on the stock.
5/13/2025 – Kymera Therapeutics had its price target lowered by analysts at UBS Group AG from $72.00 to $70.00. They now have a “buy” rating on the stock.
5/12/2025 – Kymera Therapeutics had its price target lowered by analysts at Bank of America Co. from $47.00 to $44.00. They now have a “neutral” rating on the stock.
5/12/2025 – Kymera Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $52.00 price target on the stock.

Kymera Therapeutics Stock Down 0.7%

NASDAQ KYMR opened at $46.96 on Monday. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The stock’s 50-day moving average price is $32.72 and its 200-day moving average price is $35.71. The company has a market capitalization of $3.06 billion, a P/E ratio of -20.07 and a beta of 2.07.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $11.38 million. During the same quarter last year, the business posted ($0.69) earnings per share. The firm’s revenue was up 114.6% on a year-over-year basis. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, Director Elena Ridloff sold 12,000 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total transaction of $553,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently made changes to their positions in the business. State of Wyoming purchased a new position in Kymera Therapeutics during the 4th quarter valued at approximately $45,000. GF Fund Management CO. LTD. purchased a new position in Kymera Therapeutics during the 4th quarter valued at approximately $55,000. KBC Group NV grew its holdings in Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after buying an additional 328 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics during the 1st quarter valued at approximately $68,000. Finally, Advisors Asset Management Inc. grew its holdings in Kymera Therapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock valued at $136,000 after buying an additional 2,230 shares in the last quarter.

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.